A recent analysis of retrospective clinical data on patients with systemic lupus erythematosus (SLE) at 14 Canadian centers found that a surprisingly high proportion—at least one-third—had active disease at any point over five years of data collection.1 It has been a longstanding belief among clinicians that SLE becomes less active over time, although its accumulation…
Low-Density Granulocytes Activate T Cells in SLE
Recent research indicates that low-density neutrophils, such as low-density granulocytes, exert proinflammatory effects on the T cells of SLE patients. In the study, researchers confirmed SLE patients had a higher prevalence of low-density granulocytes than healthy controls and that these cells appeared to promote a Th1 response…
Insight into Clinical Trials for Lupus
Research into lupus treatments suffered a setback after the failure of anifrolumab in clinical trials. However, during the 2019 ACR State-of-the-Art Clinical Symposium, Richard Furie, MD, outlined the possibilities of multiple new lupus therapies under investigation…
The Little-Known (But Not Uncommon) SSc-Lupus Overlap Syndrome
What happens when systemic sclerosis (SSc) overlaps with other systemic autoimmune rheumatic diseases? Patients with either diffuse cutaneous or limited cutaneous SSc sometimes develop systemic lupus erythematosus (SLE) as well. A new, large cohort study published in the Journal of Rheumatology reveals details on the epidemiology, clinical signs and survival data of SSc-SLE overlap syndrome.1…
Update on Accelerating Medicines Partnership
The Accelerating Medicines Partnership (AMP) was launched in 2014 as a public-private partnership to spur development of new therapeutic options for rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Five years in, this unprecedented public-private effort is achieving its major milestones and yielding tools to accelerate potential new drug discoveries. The Rheumatology Research Foundation is…
New Study Examines Cerebrovascular Events in Lupus Patients
Stroke and transient ischemia are the most common cerebrovascular events in lupus patients, and a new study has found most of these occurrences can be attributed to lupus itself rather than other causes. The study, published in the October 2018 issue of Arthritis Care & Research, looked at the frequency, association and outcomes of cerebrovascular…
Characterization of Autoreactive B Cells in Patients with SLE & RA
Antibody-secreting cells are important for the pathophysiology of SLE and RA, but researchers have been unable to determine how these cells are activated. A new technique is able to distinguish between naïve autoreactive B cells and established antibody secreting cells…
Anti-Mitochondrial Antibodies & Systemic Lupus Erythematosus
Although antimitochondrial antibodies are present in SLE patients, researchers have has difficulty investigating the phenomenon due to barriers in isolating pure mitochondria. The study describes a technique that allows for such an investigation and provides insight into how the adaptive immune system recognizes mitochondrial organelles…
The ACR Supports Its Members Via Collaboration
We all know words can be powerful. They often resonate with several levels of meaning, enriching our understanding and broadening our perspective. Take the word promise, for example. It implies responsibility, as in, “We promise to do it.” It is also imbued with hope, as in “This idea has great promise.” At the ACR we…
To Bridge Health Disparities, Diagnose Lupus Early & Improve Access
CHICAGO—At the 2018 ACR/ARHP Annual Meeting, rheumatologist project volunteers for the ACR’s Collaborative Initiatives talked about their efforts to educate primary-care providers, patients and families in their communities about systemic lupus erythematosus (SLE). Their goal is to facilitate timely diagnosis and treatment of lupus, especially in underserved communities. Health Disparities Health disparities, or differences in health…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 40
- Next Page »